Phillip Minar
Children's Hospital Medical Center, Cincinnati
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Phillip Minar as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:46 UTC. Open this list on ClinicalTrials.gov
- Ph2/Ph3NCT05660746 · Precise Infliximab Exposure and Pharmacodynamic ControlChildren's Hospital Medical Center, Cincinnati · recruiting · Crohn Disease · principal investigator
- Ph2/Ph3NCT04974099 · Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's DiseaseChildren's Hospital Medical Center, Cincinnati · terminated · Crohn Disease · principal investigator
- N/ANCT04131504 · Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)Children's Hospital Medical Center, Cincinnati · completed · Crohn's Disease, IBD · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:46 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Pediatric Gastroenterology and Nutrition Training GrantT32DK007727 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2026 · $522,425 awarded in 2026Same name and institution; not confirmed by an ID
- Precise Infliximab Exposure and Pharmacodynamic Control to Achieve Deep Remission in Pediatric Crohn's DiseaseR01DK132408 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2022 to 2026 · $655,158 awarded in 2026Grant number is on one of their registry trials
- Pharmacokinetic Evaluation to Optimize Infliximab Monotherapy with Personalized Pharmacodynamic BiomarkersR03DK118314 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2018 to 2019 · $119,250 awarded in 2019Same name and institution; not confirmed by an ID
- Therapeutic Monitoring and Targeting of Neutrophil Activation in Pediatric IBDK23DK105229 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · fiscal years 2015 to 2018 · $189,945 awarded in 2018Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:46 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Comparative Effectiveness of Anti-TNF in Combination With Low-Dose Methotrexate vs Anti-TNF Monotherapy in Pediatric Crohn's Disease: A Pragmatic Randomized Trial.Gastroenterology · 202342 citationsRCR 5.2
- High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease.Am J Gastroenterol · 202411 citationsRCR 2.2
- HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's Disease.Am J Gastroenterol · 20256 citationsRCR 1.9
- Pilot trial of iBDecide: Evaluating an online tool to facilitate shared decision making for adolescents and young adults with ulcerative colitis.Health Expect · 20225 citationsRCR 0.5
- Low Anti-Tumor Necrosis Factor Levels During Maintenance Phase Are Associated With Treatment Failure in Children With Crohn's Disease.Inflamm Bowel Dis · 20253 citationsRCR 1.2